EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Exploring computational approaches to design mRNA Vaccine against vaccinia and Mpox viruses

Elijah K Oladipo iD, Olanrewaju D Oyelakin, Abdulsamad O Aiyelabegan, Elizabeth O Olajide, Victoria O Olatayo, Kaothar P Owolabi, Yewande B Shittu, Rhoda O Olugbodi, Hezekiah A Ajala, Raji A Rukayat, Deborah O Olayiwola, Boluwatife A Irewolede und 10 weitere

Immunity, Inflammation and Disease · 2024

DOI: 10.1002/iid3.1360 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Immunity, Inflammation and Disease, 2024. Verfasst von Elijah K Oladipo und 21 weiteren Autor:innen. Beteiligte Einrichtung: Division of Vaccine Design and Development, Helix Biogen Institute, Ogbomoso, Oyo State, Nigeria. Hauptthemen laut MEDLINE: Vaccinia virus, Computational Biology, mRNA Vaccines. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Messenger RNA (mRNA) vaccines emerged as a powerful tool in the fight against infections. Unlike traditional vaccines, this unique type of vaccine elicits robust and persistent innate and humoral immune response with a unique host cell‐mediated pathogen gene expression and antigen presentation.

Methods

This offers a novel approach to combat poxviridae infections. From the genome of vaccinia and Mpox viruses, three key genes (E8L, E7R, and H3L) responsible for virus attachment and virulence were selected and employed for designing the candidate mRNA vaccine against vaccinia and Mpox viral infection. Various bioinformatics tools were employed to generate (B cell, CTL, and HTL) epitopes, of which 28 antigenic and immunogenic epitopes were selected and are linked to form the mRNA vaccine construct. Additional components, including a 5′ cap, 5′ UTR, adjuvant, 3′ UTR, and poly(A) tail, were incorporated to enhance stability and effectiveness. Safety measures such as testing for human homology and in silico immune simulations were implemented to avoid autoimmunity and to mimics the immune response of human host to the designed mRNA vaccine, respectively. The mRNA vaccine's binding affinity was evaluated by docking it with TLR‐2, TLR‐3, TLR‐4, and TLR‐9 receptors which are subsequently followed by molecular dynamics simulations for the highest binding one to predict the stability of the binding complex.

Results

With a 73% population coverage, the mRNA vaccine looks promising, boasting a molecular weight of 198 kDa and a molecular formula of C 8901 H 13609 N 2431 O 2611 S 48 and it is said to be antigenic, nontoxic and nonallergic, making it safe and effective in preventing infections with Mpox and vaccinia viruses, in comparison with other insilico‐designed vaccine for vaccinia and Mpox viruses.

Conclusions

However, further validation through in vivo and in vitro techniques is underway to fully assess its potential.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Vaccinia virusComputational BiologymRNA VaccinesHumansPoxviridae InfectionsVacciniaVaccines, SyntheticRNA, MessengerViral VaccinesEpitopes, B-LymphocyteVaccine DevelopmentEpitopes, T-LymphocyteMpox, Monkeypox

Stichwörter der Autor:innen

Mpox virusPox virusesimmunoinformaticsmRNA vaccinevaccine designvaccinia virus

Substanzen

mRNA VaccinesVaccines, SyntheticRNA, MessengerViral VaccinesEpitopes, B-LymphocyteEpitopes, T-Lymphocyte

Autor:innen und Institutionen

  • Division of Vaccine Design and Development, Helix Biogen Institute, Ogbomoso, Oyo State, Nigeria.
  • Laboratory of Molecular Biology, Immunology and Bioinformatics, Department of Microbiology, Adeleke University, Ede, Osun State, Nigeria.
  • Molecular Biology and Biotechnology Department, Nigeria Institute of Medical Research, Lagos, Nigeria.
  • Department of Natural Sciences, Precious Cornerstone University, Ibadan, Oyo State, Nigeria.
  • African Centre for Disease Control HQ, Addis Ababa, Ethiopia.
  • Department of Microbiology, University of Ilorin, Ilorin, Kwara State, Nigeria.

ORCID-Profile: Elijah K Oladipo, Olumide F Ajani, Helen Onyeaka

Zitieren

APA

Oladipo, E. K., Oyelakin, O. D., Aiyelabegan, A. O., Olajide, E. O., Olatayo, V. O., Owolabi, K. P., Shittu, Y. B., Olugbodi, R. O., Ajala, H. A., Rukayat, R. A., Olayiwola, D. O., Irewolede, B. A., Jimah, E. M., Oloke, J. K., Ojo, T. O., Ajani, O. F., Iwalokun, B. A., Kolawole, O. M., Ariyo, O. E., …, & Onyeaka, H. (2024). Exploring computational approaches to design mRNA Vaccine against vaccinia and Mpox viruses. Immunity, Inflammation and Disease. https://doi.org/10.1002/iid3.1360

Vancouver

Oladipo EK, Oyelakin OD, Aiyelabegan AO, Olajide EO, Olatayo VO, Owolabi KP, et al. Exploring computational approaches to design mRNA Vaccine against vaccinia and Mpox viruses. Immunity, Inflammation and Disease. 2024. doi:10.1002/iid3.1360

BibTeX
@article{Oladipo2024,
  author = {Oladipo, Elijah K and Oyelakin, Olanrewaju D and Aiyelabegan, Abdulsamad O and Olajide, Elizabeth O and Olatayo, Victoria O and Owolabi, Kaothar P and Shittu, Yewande B and Olugbodi, Rhoda O and Ajala, Hezekiah A and Rukayat, Raji A and Olayiwola, Deborah O and Irewolede, Boluwatife A and Jimah, Esther M and Oloke, Julius K and Ojo, Taiwo O and Ajani, Olumide F and Iwalokun, Bamidele A and Kolawole, Olatunji M and Ariyo, Olumuyiwa E and Adediran, Daniel A and Olufemi, Seun E and Onyeaka, Helen},
  title = {Exploring computational approaches to design mRNA Vaccine against vaccinia and Mpox viruses},
  journal = {Immunity, Inflammation and Disease},
  year = {2024},
  doi = {10.1002/iid3.1360}
}
Kostenlos starten →